Byorna provides a proprietary eukaryotic cell‑based platform that produces therapeutic messenger RNA within a protected subcellular compartment, isolating the mRNA from RNases to preserve integrity. The system combines engineered recombinant cell lines, a patented capsule isolation method, and integrated upstream‑downstream processes to deliver high‑yield, GMP‑grade mRNA at reduced cost, targeting pharma and biotech companies developing mRNA therapeutics and vaccines.
Funding
$1.8M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current mRNA therapeutic manufacturing relies on in vitro transcription processes that are costly, scale‑limited, and prone to RNA degradation, making large‑scale production expensive and inefficient.
Solution
Byorna develops a proprietary eukaryotic cell‑based platform that produces therapeutic messenger RNA within a protected subcellular compartment. The engineered cell line maximizes expression of the target mRNA while sequestering it away from RNases, preserving integrity. After accumulation, the mRNA‑laden capsules are harvested using industrial extraction and purification steps to achieve GMP‑grade purity. This biologically driven approach reduces production costs, increases yield, and enables scalable manufacturing of high‑quality mRNA for therapeutic applications.
Target Audience
Primary customers are pharmaceutical and biotechnology companies developing mRNA‑based therapeutics, vaccines, and gene‑editing treatments that require cost‑effective, large‑scale manufacturing.
Features
- Recombinant eukaryotic cell line engineered to overexpress and compartmentalize specific mRNA sequences
- Patented subcellular “capsule” system that isolates mRNA from intracellular RNases, enhancing stability
- Integrated upstream (cell culture) and downstream (extraction, purification) processes optimized for high‑purity GMP‑grade product
- Master Cell Bank strategy ensures consistent batch‑to‑batch performance and regulatory compliance
- Real‑time quality control analytics at each production stage to monitor integrity and potency